Boehringer Ingelheim

http://www.boehringer-ingelheim.com

11.07.2000 – 17:22
Data Shows VIRAMUNE(R) (nevirapine) Well Tolerated and Effective for Prevention of Mother-to-child Transmission of HIV - More than 1,300 South African Women Participate in Landmark SAINT Trial
Durban, South Africa (ots-PRNewswire) - Results demonstrating that VIRAMUNE(R) (nevirapine) is well tolerated and effective in the prevention of mother-to-child transmission (MTCT) of HIV were presented today at the 13th International AIDS Conference. While VIRAMUNE is not currently indicated for the prevention ...
mehr
07.07.2000 – 11:00
Boehringer Ingelheim Offers VIRAMUNE(R) (nevirapine) Free of Charge to Developing Economies for the Prevention of HIV-1 Mother-to-Child Transmission
Ingelheim, Germany (ots-PRNewswire) - Boehringer Ingelheim announced today that VIRAMUNE(R) will be offered free of charge for a period of five years for the prevention of mother-to-child transmission (MTCT) of HIV-1 in developing economies. This initiative is part of Boehringer Ingelheim's commitment to the ...
mehr
11.05.2000 – 16:14
Boehringer Ingelheim Joins Largest-Ever Global Program with United Nations Agencies to Accelerate Access to HIV/AIDS Care and Treatment in Developing Countries
Ingelheim, Germany (ots-PRNewswire) - Boehringer Ingelheim announced today that, as one of five leading pharmaceutical companies, it is joining a new initiative with United Nations organisations to explore ways to accelerate and improve the provision of HIV/AIDS-related care and treatment in developing ...
mehr
15.03.2000 – 16:14
Boehringer Ingelheim weist negative Beurteilung des Schmerzmittels Thomapyrin durch die Stiftung Warentest entschieden zurück
Ingelheim (ots) - Boehringer Ingelheim weist Kritik an der Wirksamkeit des Schmerzmittels Thomapyrin" mit allem Nachdruck zurück. Bei der Vorstellung des "Handbuchs Medikamente" der Stiftung Warentest am Mittwoch in Berlin waren entsprechende Behauptungen aufgestellt worden. Bei Thomapyrin handelt es ...
mehr
13.03.2000 – 09:31
Researchers Focus on Simple, Potent Therapies as Key Component to the Management of HIV Infection in the 21st Century
TAORMINA, Italy (ots-PRNewswire) - More than 750 European physicians convened here to discuss results of important clinical trials confirming the efficacy of the anti-HIV drug VIRAMUNE(R) (nevirapine) for the treatment of HIV-infected patients. Studies relating to adult and paediatric HIV treatment, as well ...
mehr
25.02.2000 – 09:30
Zulassungserweiterung für Kombinationsschmerzmittel in den USA
Ingelheim (ots) - In den USA wurde die Zulassung der Wirkstoffkombination aus Acetylsalicylsäure, Paracetamol und Coffein für alle Formen der Migräne erweitert. Das Kombinationsschmerzmittel Excedrin Migraine, das in seiner Zusammensetzung den Thomapyrin(r) Schmerztabletten entspricht, ist somit als einziges rezeptfreies Schmerzmittel für die Behandlung der ...
mehr

29.01.2000 – 16:13
Boehringer Ingelheim Acquires New HIV/AIDS Drug from Pharmacia & Upjohn
INGELHEIM, Germany (ots-PRNewswire) - Boehringer Ingelheim and Pharmacia & Upjohn (NYSE: PNU) announced today that Boehringer Ingelheim has acquired worldwide rights for Pharmacia & Upjohn's investigational protease inhibitor, tipranavir. Under the agreement, Boehringer Ingelheim will have exclusive commercial rights to tipranavir in all markets worldwide. ...
mehr
19.01.2000 – 19:04
International HIV/AIDS Community Gains Access To Updated USA Treatment Guidelines / New Recommendations for First-Line Treatment
Ingelheim, Germany (ots-PRNewswire) - The Journal of the American Medical Association (JAMA) today published HIV/AIDS treatment guidelines updated by the International AIDS Society's (IAS) USA Panel on antiretroviral therapy use in adult HIV-1 infection. The updated guidelines reflect the increasingly important ...
mehr

Vorherige1234567